June 12, 2023 06:42 AM EDT
People
Startups
Cell/Gene Tx

Re­ju­ve­nate Bio shrinks staff, pipeline fo­cus as George Church spin­out eyes 2024 gene ther­a­py IND

Kyle LaHucik

Senior Reporter

Like many oth­er biotechs in this mar­ket en­vi­ron­ment, small gene ther­a­py mak­er Re­ju­ve­nate Bio has strug­gled to re­ju­ve­nate its bank ac­count.

The San Diego start­up …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times